NeoisoliquiritigeninCAS# 7014-39-3 |
- Isoliquiritin
Catalog No.:BCN5945
CAS No.:5041-81-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 7014-39-3 | SDF | Download SDF |
| PubChem ID | 72728334.0 | Appearance | Powder |
| Formula | C21H22O9 | M.Wt | 418.39 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Synonyms | Neoisoliquiritine | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 1-(2,4-dihydroxyphenyl)-3-[4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one | ||
| SMILES | C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)OC3C(C(C(C(O3)CO)O)O)O | ||
| Standard InChIKey | YNWXJFQOCHMPCK-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H22O9/c22-10-17-18(26)19(27)20(28)21(30-17)29-13-5-1-11(2-6-13)3-8-15(24)14-7-4-12(23)9-16(14)25/h1-9,17-23,25-28H,10H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Neoisoliquiritigenin Dilution Calculator
Neoisoliquiritigenin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3901 mL | 11.9506 mL | 23.9011 mL | 47.8023 mL | 59.7529 mL |
| 5 mM | 0.478 mL | 2.3901 mL | 4.7802 mL | 9.5605 mL | 11.9506 mL |
| 10 mM | 0.239 mL | 1.1951 mL | 2.3901 mL | 4.7802 mL | 5.9753 mL |
| 50 mM | 0.0478 mL | 0.239 mL | 0.478 mL | 0.956 mL | 1.1951 mL |
| 100 mM | 0.0239 mL | 0.1195 mL | 0.239 mL | 0.478 mL | 0.5975 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 6-Acetyl-7-hydroxy-2,3-dimethylchromone
Catalog No.:BCX1185
CAS No.:225518-70-7
- Heterophyllin J
Catalog No.:BCX1184
CAS No.:660397-15-9
- 5-Methoxyafrormosin 7-O-glucoside
Catalog No.:BCX1183
CAS No.:64656-92-4
- Acetylarenobufagin
Catalog No.:BCX1182
CAS No.:184673-79-8
- N-Acetyl-D-lactosamine
Catalog No.:BCX1181
CAS No.:32181-59-2
- GDP-L-Fuc.2Na
Catalog No.:BCX1180
CAS No.:15839-70-0
- 11-Oxo-ganoderic acid DM
Catalog No.:BCX1179
CAS No.:1408244-15-4
- 2-Hydroxypinocembrin
Catalog No.:BCX1178
CAS No.:40489-17-6
- Halofuginone hydrobromide
Catalog No.:BCX1177
CAS No.:64924-67-0
- Glucovanillin
Catalog No.:BCX1176
CAS No.:494-08-6
- Aloenin B
Catalog No.:BCX1175
CAS No.:106533-41-9
- 7-Oxo-ganoderic acid Z2
Catalog No.:BCX1174
CAS No.:1446104-52-4
- Rubropunctamine
Catalog No.:BCX1187
CAS No.:514-66-9
- Glycyrrhizic acid methyl ester
Catalog No.:BCX1188
CAS No.:104191-95-9
- Kissoone A
Catalog No.:BCX1189
CAS No.:903559-01-3
- Deoxycytidine
Catalog No.:BCX1190
CAS No.:951-77-9
- Daucosterin acetate
Catalog No.:BCX1191
CAS No.:4282-00-2
- (-)-3-Demethylcolchicine
Catalog No.:BCX1192
CAS No.:7336-33-6
- Ludaconitine
Catalog No.:BCX1193
CAS No.:82144-72-7
- Syringopicroside
Catalog No.:BCX1194
CAS No.:29118-80-7
- Taccalonolide C
Catalog No.:BCX1195
CAS No.:117803-96-0
- Complanatuside 6"-malonate
Catalog No.:BCX1196
CAS No.:2089462-18-8
- Resinacein C
Catalog No.:BCX1197
CAS No.:1309931-92-7
- Markogenin
Catalog No.:BCX1198
CAS No.:562-35-6
Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-beta- catenin Signaling in Breast Cancer.[Pubmed:28914191]
Curr Cancer Drug Targets. 2018;18(4):390-399.
BACKGROUND: Breast cancer mortality has been stable or decreasing in the world, its incidence and recurrence rates have sharply risen worldwide in the recent years. OBJECTIVE: To investigate the clinicopathological significance and potential function of GRP78 in the development and progression of breast cancer. To explore the effects of Neoisoliquiritigenin (NISL) in breast cancer and the underlying mechanism. METHOD: GRP78 was detected by immunohistochemistry (IHC) using breast cancer tissue microarrays (TMAs), and the association between GRP78 levels and clinicopathological factors and prognosis was analyzed. The functional effects of GRP78 on breast cancer were validated by an MTT assay, foci formation assay, Matrigel invasion assay and mouse xenograft assay. The effects of NISL were tested by an MTT assay, apoptosis assay and mouse xenograft assay. A LigandFit algorithm, ATPase activity assay, western blot and IHC assay were used to discover the underlying mechanism of the effects of NSIL. RESULTS: GRP78 was highly expressed in breast cancer cell lines and tissues. In addition, high expression of GRP78 was correlated to poor outcomes and distant metastasis. Functional experiments showed that GRP78 promoted breast cancer proliferation and invasion in vitro and in vivo. NISL inhibited cell proliferation and induced cell apoptosis in breast cancer by directly binding to GRP78 to regulate the beta-catenin pathway. CONCLUSION: Taken together, these results highlighted the significance of GRP78 in breast cancer development and suggested NISL as a natural candidate to inhibit breast cancer by targeting GRP78 and beta-catenin signaling.
The application of HPLC-MS/MS to studies of pharmacokinetics and interconversion of isoliquiritigenin and neoisoliquiritigenin in rats.[Pubmed:26577957]
Biomed Chromatogr. 2016 Jul;30(7):1155-1161.
A specific and sensitive HPLC-MS/MS method was developed and validated for the simultaneously quantification of isoliquiritigenin (ISL) and neoisoliquiritin (NIS) in rat plasma by oral administration. Analytes were analyzed on an Agilent 6460 LC-MS/MS system (Agilent, USA) using an Agilent Zorbax SB-C18 column (4.6 x 150 mm, 5 mum). Gradient elution was applied for the analyte separation using a mobile phase composed of 0.1% formic acid aqueous solution and methanol at a flow rate of 1.0 mL/min with a total running time of 12 min. The calibration curves for ISL and NIS showed good linearity in the concentrations ranging from 0.001 to 4.000 mug/mL with correlation coefficients >0.998. The precision, accuracy, recovery and stability were deemed acceptable. The method was applied to the pharmacokinetics study of ISL and NIS in rats by single and combination administration. The result showed that Cmax and AUC0-->t of ISL were markedly increased from 0.53 to 1.20 mug/mL, and from 69.63 to 200.74 min mug/mL by combination administration. The mean t1/2 value was also prolonged from 64.55 to 203.74 min in the combination group. These results indicated that NIS may have been metabolized to ISL which increased the absorption and extended the elimination of ISL. However, little difference was found for NIS pharmacokinetics parameters between single NIS and the combination group, which suggested that there was no significant biotransformation of ISL to NIS. Copyright (c) 2015 John Wiley & Sons, Ltd.
Bioactive constituents of Spatholobus suberectus in regulating tyrosinase-related proteins and mRNA in HEMn cells.[Pubmed:16782143]
Phytochemistry. 2006 Jun;67(12):1262-70.
Spatholobus suberectus Dunn (Leguminosae) is a traditional Chinese herbal medicine used to treat rheumatism, anemia, menoxenia, and other disorders. The extent to which this herbal medicine is useful to skin cells, however, has not been evaluated. Constituents of the 95% ethanol extracts of the dried vine stems of S. suberectus were therefore isolated and examined for their skin-whitening capacity. A bio-guided phytochemical investigation, involving use of the mushroom tyrosinase inhibitory system, of active fractions of the extracts resulted in the isolation of 12 constituents. The structures of these constituents, which were characterized by various spectroscopic techniques, consisted of one flavone, three isoflavones, five flavanones, two flavanonols, and one chalcone. Of these constituents 3',4',7-trihydroxyflavone (1), eriodictyol (3), plathymenin (5), dihydroquercetin (6), butin (7), Neoisoliquiritigenin (8), dihydrokaempferol (9), liquiritigenin (10), and 6-methoxyeriodictyol (12) represented compounds isolated for the first time from S. suberectus. These constituents were evaluated their ability to inhibit cellular tyrosinase activity and for their melanin inhibitory activity in human epidermal melanocytes (HEMn). Butin (7) was the most efficacious of these constituents and exhibited concentration-dependent effects. Western blot analysis revealed that expression of tyrosinase and tyrosinase-related proteins 1 and 2 (TRP1 and TRP2) was decreased in butin (7)-treated HEMn cells. Additionally, quantitative real-time PCR (qRT-PCR) analysis disclosed that expression of mRNAs for tyrosinase, TRP1 and TRP2 was suppressed by butin (7). It is concluded that butin (7) is the most active of the components of S. suberectus in inhibiting pigmentation and that this inhibition is exerted through inhibition of transcription of the genes encoding tyrosinase, TRP1 and TRP2.
